Full View

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian… - The …, 2015 - academic.oup.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …
被引用次数：76 相关文章
[PDF] academia.edu

[PDF][PDF] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF HEIGENER, C SCHUMANN, M SEBASTIAN… - 2015 - academia.edu
ABSTRACT Background. Afatinib, an irreversible ErbB family blocker, is approved for
treatment of patients with previously untreated non-small cell lung cancer (NSCLC) …

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

DF Heigener, C Schumann, M Sebastian… - The …, 2015 - europepmc.org
Background Afatinib, an irreversible ErbB family blocker, is approved for treatment of
patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating …
[HTML] nih.gov

[HTML][HTML] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian… - The …, 2015 - ncbi.nlm.nih.gov
ABSTRACT Background. Afatinib, an irreversible ErbB family blocker, is approved for
treatment of patients with previously untreated non-small cell lung cancer (NSCLC) …
[PDF] wiley.com

[PDF][PDF] Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian… - The …, 2015 - Wiley Online Library
Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of
patients with previously untreated non‐small cell lung cancer (NSCLC) harboring activating …

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian, P Sadjadian… - The Oncologist, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background.</jats: title>< jats: p>
Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with …

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Afatinib, an irreversible ErbB family blocker, is approved for treatment of
patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating …

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF Heigener, C Schumann, M Sebastian… - …, 2015 - kups.ub.uni-koeln.de
Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of
patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating …
[PDF] researchgate.net

[PDF][PDF] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

DF HEIGENER, C SCHUMANN, M SEBASTIAN… - 2015 - researchgate.net
ABSTRACT Background. Afatinib, an irreversible ErbB family blocker, is approved for
treatment of patients with previously untreated non-small cell lung cancer (NSCLC) …

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

DF Heigener, C Schumann, M Sebastian… - …, 2015 - search.ebscohost.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …